Anti-Human PCSK9 Antibody (SAA0159) (HV275207)

Fiche technique Partager le produit Copier les informations

Prix(USD) : $

Spécification :

50ug
100ug

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique

Aperçu

Numéro de catalogue	HV275207
Description	Anti-Human PCSK9 Antibody (SAA0159) [SAA0159] (HV275207) is a human monoclonal antibody detecting PCSK9 in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications.
Reactivité des espèces	Human
Applications	FCM
Espèce hôte	Human
Isotype	IgG4, kappa
ID de clone	SAA0159
Clonalité	Monoclonal
Cible	Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Niveau d'endotoxines	Please contact with the lab for this information.
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q8NBP7
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Contexte	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha). 1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658 2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796 3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702 4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458 5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827 6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
Note	For research use only.

Images

Flow Cytometry

Flow-cytometry using anti-human PCSK9 antibody.PCSK9 Transfected CHO cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human PCSK9 antibody monoclonal antibody (Catalog # HV275207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.
Flow Cytometry

Flow-cytometry using anti-human PCSK9 antibody.Human Jurkat cell line were stained with an irrelevant antibody (Blue Histogram) or an anti-human PCSK9 antibody monoclonal antibody (Catalog # HV275207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.
Flow Cytometry

Flow-cytometry using anti-human PCSK9 antibody.HeLa cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human PCSK9 antibody monoclonal antibody (Catalog # HV275207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.